Equity research analysts tracking Australian Clinical Labs Limited (ASX: ACL) maintain a median 12-month consensus price target hovering around A2.40toA2.85 per share, with higher optimistic estimates reaching up to A3.65orA3.85, and lower conservative targets anchored near A$2.08. These predictions reflect varying perspectives on pathology volume recoveries, operational efficiencies from automated laboratory systems, and ongoing adjustments to government healthcare reimbursement schedules across Australia.